Home - Products - MAPK/ERK Signaling - p38 MAPK - TAK1-IN-3

TAK1-IN-3

CAS No. 494772-87-1

TAK1-IN-3( —— )

Catalog No. M35215 CAS No. 494772-87-1

TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	70	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

TAK1-IN-3
Note

Research use only, not for human use.
Brief Description

TAK1-IN-3 is a novel ATP-competitive TAK1 inhibitor for the study of cancer.
Description

TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

MAPK/ERK Signaling
Target

p38 MAPK
Recptor

MAPK
Research Area

——
Indication

——

Chemical Information

CAS Number

494772-87-1
Formula Weight

317.41
Molecular Formula

C16H19N3O2S
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (315.05 mM; Ultrasonic )
SMILES

O=C(N)C=1SC(=CC1N)C=2C=CC(=CC2)CN3CCOCC3
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Maohuoside A

Maohuoside A promotes osteogenesis of rat mesenchymal stem cells via BMP and MAPK signaling pathways.
MK2-IN-3

MK2-IN-3 is a potent, cell-permeable inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) and can be used for the treatment of rheumatoid arthritis
DAMGO

DAMGO is an opioid receptor agonist with the ability to affect the locomotive activity in rodents. Possible analgesic agent due to μ-opiod receptor interaction.

Sign In Join Free